Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden

Fig. 2

Increased proliferation and activation of CD8+ T cells in peripheral blood of PegINFα treated patients. PBMC collected prior to and after at least 10 weeks of treatment were analyzed using anti-CD3, -CD8, -CD38, -HLA-DR and Ki-67 antibodies. Percentage of CD8+ T cells, cycling (Ki-67+) CD8+ T cells and CD38+/HLA-DR+ CD8+ T cells are shown in (a–c) respectively

Back to article page